全文获取类型
收费全文 | 709980篇 |
免费 | 50353篇 |
国内免费 | 1333篇 |
专业分类
耳鼻咽喉 | 9306篇 |
儿科学 | 23298篇 |
妇产科学 | 17790篇 |
基础医学 | 110979篇 |
口腔科学 | 20155篇 |
临床医学 | 63931篇 |
内科学 | 135410篇 |
皮肤病学 | 16293篇 |
神经病学 | 49921篇 |
特种医学 | 26053篇 |
外国民族医学 | 77篇 |
外科学 | 105695篇 |
综合类 | 14825篇 |
现状与发展 | 2篇 |
一般理论 | 161篇 |
预防医学 | 51330篇 |
眼科学 | 16365篇 |
药学 | 54444篇 |
3篇 | |
中国医学 | 2325篇 |
肿瘤学 | 43303篇 |
出版年
2019年 | 5530篇 |
2018年 | 7987篇 |
2017年 | 6201篇 |
2016年 | 6911篇 |
2015年 | 7662篇 |
2014年 | 10449篇 |
2013年 | 15570篇 |
2012年 | 20882篇 |
2011年 | 21936篇 |
2010年 | 12981篇 |
2009年 | 12190篇 |
2008年 | 20405篇 |
2007年 | 21954篇 |
2006年 | 22349篇 |
2005年 | 20872篇 |
2004年 | 20445篇 |
2003年 | 19314篇 |
2002年 | 18870篇 |
2001年 | 36621篇 |
2000年 | 37180篇 |
1999年 | 30522篇 |
1998年 | 7644篇 |
1997年 | 6393篇 |
1996年 | 6660篇 |
1995年 | 6674篇 |
1994年 | 6128篇 |
1993年 | 5636篇 |
1992年 | 23188篇 |
1991年 | 23141篇 |
1990年 | 22533篇 |
1989年 | 22270篇 |
1988年 | 20194篇 |
1987年 | 19572篇 |
1986年 | 18602篇 |
1985年 | 17449篇 |
1984年 | 12788篇 |
1983年 | 10827篇 |
1982年 | 5942篇 |
1979年 | 11559篇 |
1978年 | 8177篇 |
1977年 | 6873篇 |
1976年 | 6613篇 |
1975年 | 7308篇 |
1974年 | 8541篇 |
1973年 | 8175篇 |
1972年 | 7699篇 |
1971年 | 7152篇 |
1970年 | 6905篇 |
1969年 | 6342篇 |
1968年 | 5832篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
21.
IntroductionHip displacement is common in cerebral palsy (CP) and is related to the severity of neurological and functional impairment. It is a silent, but progressive disease, and can result in significant morbidity and decreased quality of life, if left untreated. The pathophysiology of hip displacement in CP is a combination of hip flexor-adductor muscle spasticity, abductor muscle weakness, and delayed weight-bearing, resulting in proximal femoral deformities and progressive acetabular dysplasia. Due to a lack of symptoms in the early stages of hip displacement, the diagnosis is easily missed. Awareness of this condition and regular surveillance by clinical examination and serial radiographs of the hips are the key to early diagnosis and treatment.Hip surveillance programmesSeveral population-based studies from around the world have demonstrated that universal hip surveillance in children with CP allows early detection of hip displacement and appropriate early intervention, with a resultant decrease in painful dislocations. Global hip surveillance models are based upon the patients’ age, functional level determined by the Gross Motor Function Classification system (GMFCS), gait classification, standardized clinical exam, and radiographic indices such as the migration percentage (MP), as critical indicators of progressive hip displacement.ConclusionDespite 25 years of evidence showing the efficacy of established hip surveillance programmes, there is poor awareness among healthcare professionals in India about the importance of regular hip surveillance in children with CP. There is a need for professional organizations to develop evidence-based guidelines for hip surveillance which are relevant to the Indian context. 相似文献
22.
23.
24.
25.
Ivan A. Pelevin Anton Yu. Nalivaiko Dmitriy Yu. Ozherelkov Alexander S. Shinkaryov Stanislav V. Chernyshikhin Alexey N. Arnautov Sergey V. Zmanovsky Alexander A. Gromov 《Materials》2021,14(10)
Aluminum matrix composites (AMC) are of great interest and importance as high-performance materials with enhanced mechanical properties. Al2O3 is a commonly used reinforcement in AMCs fabricated by means of various technological methods, including casting and sintering. Selective laser melting (SLM) is a suitable modern method of the fabrication of net-shape fully dense parts from AMC with alumina. The main results, achievements, and difficulties of SLM applied to AMCs with alumina are discussed in this review and compared with conventional methods. It was shown that the initial powder preparation, namely the particle size distribution, sphericity, and thorough mixing, affected the final microstructure and properties of SLMed materials drastically. The distribution of reinforcing particles tends to consolidate the near-melting pool-edges process because of pushing by the liquid–solid interface during the solidification process that is a common problem of various fabrication methods. The achievement of an homogeneous distribution was shown to be possible through both the thorough mixing of the initial powders and the precise optimization of SLM parameters. The strength of the AMCs fabricated by the SLM method was relatively low compared with materials produced by conventional methods, while for superior relative densities of more than 99%, hardness and tribological properties were obtained, making SLM a promising method for the Al-based matrix composites with Al2O3. 相似文献
26.
27.
N. Tanaka Y. Kunihiro R. Kawano T. Yujiri K. Ueda T. Gondo T. Matsumoto 《Clinical radiology》2021,76(1):50-59
28.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
29.